Lung cancer immunotherapy trial pulled before it began
NCT ID NCT06713798
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study was designed to test two immunotherapy drugs, atezolizumab and tiragolumab, in people with advanced lung cancer that has special immune cell clusters called tertiary lymphoid structures. The trial was withdrawn before enrolling any participants, so no results are available. It would have compared the drug combination to atezolizumab alone in patients who had not received prior treatment, and tested the combination in those who had already tried immunotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atezolizumab and tiragolumab
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a smart drug deliver a toxic payload directly to cancer cells?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?